NCT03126201|Completed
Loading search results
Sponsor study identifier
observational
86
1 country
1
Study Start
December 2016
Actual (reported)Primary Completion
September 2017
Actual (reported)Study Completion
November 2017
Actual (reported)Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease. In this study, our aim is to evaluate the effects of histopathological, clinical, and laboratory features of patients with primary FSGS on the disease progression.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2017
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2016
Actual (reported)April 16, 2017
Actual (reported)April 24, 2017
Actual (reported)September 2017
Actual (reported)November 2017
Actual (reported)Reduction in kidney function and/or progression to end stage renal disease
At least a fifty-percent reduction in baseline estimated glomerular filtration rate (eGFR) or development of kidney failure, which was defined as a category G5 CKD (eGFR \<15 ml/min/1.73 m2).
5-10 years
Complete remission
5-10 years
Partial remission
5-10 years
Patients with biopsy-proven primary focal segmental glomerulosclerosis.
Patients with biopsy-proven primary focal segmental glomerulosclerosis.
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
Istanbul, 34093, Turkey (Türkiye)
D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011 Dec 22;365(25):2398-411. doi: 10.1056/NEJMra1106556. No abstract available.
Yasar Caliskan, MD
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
86 participants (actual enrollment reported by the registry).
First Submitted
April 16, 2017
First Posted
April 24, 2017
Study Start
December 2016
Actual (reported)Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Contact the study team to confirm eligibility.
Primary Completion
September 2017
Actual (reported)Study Completion
November 2017
Actual (reported)Last Updated
February 19, 2018
Record last verified: 2018-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: